ReviewAnnual review of microbiology2022
Mining Fatty Acid Biosynthesis for New Antimicrobials.
Review in Annual review of microbiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 45 citations in OpenAlex.
- Article
- Monounsaturated fatty acid biosynthesis is critical for streptococcal envelope homeostasis and stress tolerance.Journal of bacteriology · 2026Article
- Inhibiting Bacterioferritin Iron Release Induces Iron Starvation and Metabolic Downshift, Potentiating Aminoglycosides inACS infectious diseases · 2026Article
- Diverse unsaturated fatty acids bypass loss of FabH-catalysed initiation of fatty acid synthesis inMicrobiology (Reading, England) · 2026Article
- A proteome-driven strategy to discover novel therapeutic targets in Orientia tsutsugamushi.Antonie van Leeuwenhoek · 2026Article
- Rule-Based Ion Prediction with Orthogonal Constraints Reveals Bacterial Phospholipid Remodeling Signatures.Antibiotics (Basel, Switzerland) · 2026Article
- FabH (β-Ketoacyl-ACP Synthase III) -- Promising Novel Antibacterial Target and Its Inhibitors.Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents · 2026Review
- Monounsaturated fatty acid biosynthesis is critical for streptococcal envelope homeostasis and stress tolerance.bioRxiv : the preprint server for biology · 2026Article
- Lipopolysaccharide: Recent Advances in Its Biosynthesis and Controlling Cell Envelope Homeostasis.International journal of molecular sciences · 2025Article
- Combating Antimicrobial Resistance: Innovative Strategies Using Peptides, Nanotechnology, Phages,Pharmaceuticals (Basel, Switzerland) · 2025Review
- Challenges and Prospects for Eradication ofPathogens (Basel, Switzerland) · 2025Review
- The apple of discord: can spider cocoons be equipped with antimicrobial factors?-a systematic review.Frontiers in zoology · 2025Review
- Functional disparities of malonyl-ACP decarboxylase betweenApplied and environmental microbiology · 2025Article
- Identification of essential genes by transposon insertion sequencing and genome-scale metabolic model construction inMicrobiology spectrum · 2025Article
- Structure and catalytic mechanism of exogenous fatty acid recycling by AasS, a versatile acyl-ACP synthetase.Nature structural & molecular biology · 2025Article
- Exploring Oxylipins in Host-Microbe Interactions and Their Impact on Infection and Immunity.Current issues in molecular biology · 2025Review
- Homologous relationship between FabG involved in fatty acid biosynthesis and SDR on chromosome II in the multi-chromosome pathogen Vibrio anguillarum.Scientific reports · 2025Article
- Fighting Antimicrobial Resistance: Innovative Drugs in Antibacterial Research.Angewandte Chemie (International ed. in English) · 2025Review
- Exogenous fatty acids inhibit fatty acid synthesis by competing with endogenously generated substrates for phospholipid synthesis in Escherichia coli.FEBS letters · 2025Article
- PlsX and PlsY: Additional roles beyond glycerophospholipid synthesis in Gram-negative bacteria.mBio · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Antibiotic resistance is a serious public health concern, and new drugs are needed to ensure effective treatment of many bacterial infections. Bacterial type II fatty acid synthesis (FASII) is a vital aspect of bacterial physiology, not only for the formation of membranes but also to produce intermediates used in vitamin production. Nature has evolved a repertoire of antibiotics inhibiting different aspects of FASII, validating these enzymes as potential targets for new antibiotic discovery and development. However, significant obstacles have been encountered in the development of FASII antibiotics, and few FASII drugs have advanced beyond the discovery stage. Most bacteria are capable of assimilating exogenous fatty acids. In some cases they can dispense with FASII if fatty acids are present in the environment, making the prospects for identifying broad-spectrum drugs against FASII targets unlikely. Single-target, pathogen-specific FASII drugs appear the best option, but a major drawback to this approach is the rapid acquisition of resistance via target missense mutations. This complication can be mitigated during drug development by optimizing the compound design to reduce the potential impact of on-target missense mutations at an early stage in antibiotic discovery. The lessons learned from the difficulties in FASII drug discovery that have come to light over the last decade suggest that a refocused approach to designing FASII inhibitors has the potential to add to our arsenal of weapons to combat resistance to existing antibiotics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.